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ABSTRACT 
Autoimmune diseases are dependent on multifactorial factors including genes, environment and 
interactions between them. This thesis is focused on a chronic inflammatory disorder, 
Rheumatoid arthritis (RA). So far only very few genes and environmental factors have been 
identified reflecting the complexity of the autoimmune processes. Identification of new genes 
and the underlying mechanisms leading to disease progression is absolutely crucial for finding 
more specific therapies. Understanding the pathogenic events causing chronic joint destruction 
can be best done using animal models. The work in this thesis focused on well-defined mouse 
models of autoimmune diseases: collagen induced arthritis (CIA), collagen antibody induced 
arthritis (CAIA) and experimental autoimmune encephalomyelitis (EAE). We have used two 
different strategies to map the genes that influence arthritis development: congenic strains and 
heterogeneous stock inbred-outbred cross. Of particular interest in this thesis are gene regions 
previously identified in two-generation crosses between B10.Q and NOD strains; Cia9 and 
Cia2 loci that carry promising candidate genes such as FcγR cluster region and complement C5 
respectively. To be able to elucidate the role of underlying genes in arthritis in both the loci, we 
generated sub-interval congenic lines (paper III and IV). We found that FcγRIIb and FcγRIII are 
most likely candidates for the original Cia9 locus (paper III). Moreover, we were able to show 
that systemic rather than local production of complement C5 is crucial in arthritis development 
(paper IV). In order to identify additional loci controlling arthritis in mice we have used another 
genetic approach – using heterogeneous stock mice, a cross between eight different founders. 
At first, HS mice were screened for susceptibility to different animal models (paper II) and then 
CIA permissive H2q haplotype has been introduced and a large cohort of heterogeneous stock 
inbred-outbred cross was investigated for arthritis susceptibility (paper I). We found 18 new 
arthritis loci and fine mapped several already known loci including Cia9 and Cia2. The last part 
of this thesis describes the prospect of using a thermo-responsive polymer as an adjuvant (paper 
V). These results suggest mapping of causative genes in a complex disease is multifaceted and a 
challenging task.   
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INTRODUCTION 
Every day our body is challenged to protect its integrity from all dangers that can be seriously 
harmful. This is only possible due to the amazing mechanism we posses – immune system. It 
works on many phases to defend “us” against bacteria, microbes, viruses, toxins and parasites 
that are just waiting to invade us. In addition, immune system is also scanning the body to make 
sure that it’s free from internal dangers like uncontrolled cell divisions. The aim of the immune 
system is to act fast since the main feature of pathogens is to spread immediately. Thus, 
immune system consists of specialized immune cells and molecules that evolved to build a 
complex network of defence mechanisms. Usually first line of the defence is a surface barrier 
(skin, mucous membranes) or already pre-formed molecules like bactericidal lyzozyme in the 
tears or other proteins circulating in the body, called complement components. The complement 
system is in charge to destroy or label the pathogen that can be recognized by specialized 
phagocytes like macrophages or neutrophils. This part of the defence is named as innate, since it 
is unspecific and recognizes the pathogens in a generic way through pattern-recognition 
receptors (PRRs). PRRs can recognize a number of evolutionarily conserved bacterial and viral 
molecules, including lipopolysaccharides (LPS), flagellin or double stranded RNA and activate 
phagocytosis of the microbes. Engulfment of pathogens by antigen presenting cells (APC) 
initiates a series of events leading to digestion, processing and finally presentation of the 
antigen to specialized group of cells. The other cells of innate system like mast cells, 
eosinophils and basophils can release various mediators that will help to fight against the 
invading pathogens and natural killer cells are designed to kill the infected cells.  
 
Sometimes the propagation of pathogen is too pronounced and the innate mechanisms are not 
sufficient to defend against the infections, then the second line of the defence – the adaptive 
immune system is coming in to the picture.  The adaptive immune system is composed of T 
cells and antibody-producing B cells. They are able to specifically recognize the pathogens due 
to their random rearrangements of receptor genes and thus generating an enormous amount of 
unique receptors that can bind various pathogens. B cells mature in the bone marrow and they 
are important players in the humoral immune response. T cells also originate from bone marrow 
but their development takes place in thymus. They are subjected to several checkpoints before 
they will be in the periphery. There are two steps, positive and negative selection are involved 
in this process. Positive selection is recognition of peptides with histocompatibility complex 
(MHC) by T cells and those that are having sufficient affinity for peptide-MHC complex are 
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getting the survival signal and being selected. The negative selection consists of selection of 
only those T cells that do not have high affinity for self-antigens. Nevertheless, sometimes self-
reactive cells are escaping to the periphery where they can be activated. This process is called 
autoimmunity. Approximately 3-5% of the population suffer from autoimmune diseases. They 
could be either organ-specific like multiple sclerosis (MS) and type I diabetes (TID), or 
systemic, like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Even though 
autoimmune diseases are quite common, still we know very little about the mechanisms leading 
to autoimmunity. We are however now beginning to understand the complexity of the genetics 
and molecular pathways behind several autoimmune diseases.   
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RHEUMATHOID ARTHRITIS 
Rheumatoid arthritis (RA) is a clinical syndrome rather than a single disease consisting of 
distinct subsets (1) having different pathophysiological mechanisms (2) leading to disability by 
destruction of peripheral joints and bone erosions. RA is characterized by persistent synovial 
inflammation causing the swollenness and pain and is often accompanied with fatigue and 
stiffness of the joints. Usually it affects small joints of hands, feet and spine however larger 
joints like knees and shoulders can also be engaged.  RA can result in extra-articular features 
like vasculitis, rheumatoid nodules or lung inflammation and co-morbidities such as heart 
failure, stroke or cancers (3). It is considered to be an autoimmune disorder as the presence of 
autoantibodies mainly rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) 
can be recognized. RA is a common disorder affecting 0.5–1.0 % of adults in developed 
countries. Women are three times more affected than man and the onset usually occurs at fifth 
decade of life and increases with the age (4). Prevalence of disease varies geographically so that 
it is more common in North America and Northern Europe compared to developing countries 
(4-6). However, etiology of RA is unknown but it is believed that different genetic and 
environmental factors are involved in disease development. RA is not a recent disease. Already, 
the evidence of RA can be found in skeletons dated 4000-1000 BCE. The first description of 
rheumatoid arthritis in modern medicine was made by French Dr. Augustin Jacob Landre-
Beavuvais in 1800. Finally, 90 years later Archibald Garrod replaced the existing phrase 
“Rheumatic Gout” to new name “Rheumatoid Arthritis”(7, 8).  
 
DIAGNOSIS AND TREATMENT 
Since rheumatoid arthritis is not a single disease and symptoms are often similar to other 
inflammatory pathologies, patients are classified according to the specified selection of criteria. 
Recently, American College of Rheumatology (ACR) and the European League Against 
Rheumatism (EULAR) developed the new criteria for RA diagnosis (9). New set of 
classification criteria for RA has focused on early stage of the disease (10) including joint 
evaluation, duration of symptoms, serologic tests (RF or ACPA) and acute-phase response 
(ESR- erythrocyte sedimentation rate, CRP- C reactive protein) (9). The main purpose of the 
new criteria is to increase sensitivity and specificity to diagnose the early stage of RA and to 
initiate the proper disease-modifying treatment at the earliest. Though, there is still no cure for 
RA, various pharmacological treatments are available to alleviate the sufferings of the patient. 
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These include NSAIDs (non-steroidal anti-inflammatory drugs), DMARDs (disease-modifying 
anti-rheumatic drugs), glucocorticoids and biological agents.  Currently, the most commonly 
prescribed DMARD is methotrexate (MTX) but others like anti-malarial drug 
hydroxychloroquine (HCQ), sulfasalazine (SSZ) and leflunomide are also often used. They 
slow down the destructive process in bone and cartilage by suppressing the immune system, 
decreasing acute-phase markers, provide relief from pain and stiffness and generally improve 
long-term health (11). DMARDs have slower onset of action and the effect of treatment can be 
visualized after several weeks (MTX, SSZ) or even months (gold salt) after first administration 
and thus addition of non- steroidal anti-inflammatory drugs or short-term glucocorticoids during 
the flare-ups is used as an alternate. If response to the treatment is inadequate, DMARDs 
sometimes being combined (12) and given for example as a triple therapy consisting of 
methotrexate, hydroxychloroquine and sulfasalazine (13) or as a combination with anti-TNF 
(tumor necrosis factor-α) agents (14). NSAIDs like aspirin, diclofenac, and ibuprofen provide 
efficient symptomatic relief of pain and inflammation by inhibition of COX isoenzymes (COX-
1 and COX-2) and thereby reducing the level of prostaglandins. However, they do not have 
major effect on disease progression or destruction in RA. Glucocorticoids (prednisone, 
prednisolone) are given either locally into inflamed joint or as oral/intramuscular administration 
that help to reduce synovitis by decreasing the joint swelling and allowed improvement of the 
treatment with another DMARDs (15). They are able to decrease the progression of bone 
erosion, especially in patients with early RA (16). Since many treatments have adverse effects, 
monitoring of the patient’s blood counts and liver function tests is required (17). Biological 
agents are used when the therapy with DMARDs failed and arthritis progression is 
uncontrolled. They consist of either monoclonal antibodies or recombinant proteins that target 
immune molecules and cells. One of the first successfully used biological agents over the 
decade ago was TNF-α inhibitor (Infliximab), which revolutionized the rheumatology field. It 
is highly effective and inhibits leukocyte trafficking, acute-phase responses and reduces the 
destruction of the cartilage and bones. Another strategy of using monoclonal antibodies is to 
block IL-6 receptor (18) and it is mainly used in patients, who did not respond to anti-TNF-α 
treatment. In addition IL-15 (19), IL-17 (20) antagonists are under investigations and in the 
phase II clinical trials. Other therapies are directed toward depletion or inactivation of immune 
cells involved in the pathogenesis of RA. Anti-B cells therapy comprises of monoclonal 
antibodies (anti-CD20) that deplete B cells. T-cell target approach is focused on the termination 
of cell activation with a fusion protein between extracellular portion of cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and Fc fragment of a human IgG1 (CTLA4Ig) (21).  
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ENVIROMENTAL FACTORS IN RHEUMATHOID ARTHRITIS 
The aetiology of rheumatoid arthritis is still not clear. Most likely, environmental and genetic 
(including epigenetics) factors and their interactions are considered to be important triggers. It 
has been suggested that genetic factors can explain approximately 60% of the risk for 
development of RA (22, 23) and therefore environmental factors must be taken into account for 
disease outcome as well. It is most likely that there is more than one experimental factor that is 
involved in triggering RA development and those factors can interact in an additive manner (for 
ex. smoking plus infection). Cigarette smoking is one of the most potential and investigated 
risk factor for RA and it correlates in a dose dependent manner (24, 25). It has been shown that 
heavy smokers (41-50 packs/year) have thirteen folds increased risk to develop RA in both 
sexes (26). Interestingly, an interaction between shared epitopes (SE) HLA-DRB1 genes and 
smoking contributing to the development of sero-positive but not sero-negative RA has been 
found (27, 28). This phenomenon is mainly due to the citrullination of proteins that triggers 
specific autoimmunity in the patients carrying SE genes (29). 
During last few decades it was postulated that exposure to infection might also be important 
factor in RA. Both bacterial (Mycobacterium tuberculosis, Escherichia coli, Klebsiella 
pneumoniae) and viral agents (Epstein-Barr virus, parvovirus B19, Cytomegalovirus) have 
been associated with RA (30-32). Recent studies have highlighted the role of Porphyromonas 
gingivalis infection, which leads to periodontal diseases, as one of the possible mechanisms to 
trigger systemic inflammation (33, 34). Porphyromonas gingivalis expresses the enzyme 
peptidyl arginine deiminase (PAD) that may citrullinate human proteins and cause the loss of 
tolerance to self-antigens (35, 36). Therefore, periodontitis may have an impact on the 
progression of RA (34). 
 
Moreover, recent Swedish study has shown that exposure to silica dust by working in stone 
crushing or rock drilling increased the risk for RA development threefold (37). Another major 
candidate is mineral oil that has been reported to increase the risk of RA especially in 
patients RF or ACPA positive (38). Besides, mineral oil has been shown to induce 
polyarthritis in rats (39). The protective effect of Mediterranean diet has been reported as a 
factor reducing the risk of development of RA (40, 41). Especially lifelong consumption of 
cooked vegetables (42), or oily fish and olive oil have a prominent effect on RA, hypothetically 
due to the high level of omega 3 lipids, which may act anti-inflammatory factors (43). On the 
 13 
other hand, high-level red meat consumption, offal and meat fat increased the risk for the 
development of inflammatory polyarthritis (44). However, association between meat, iron or 
proteins intake and risk for RA has not been reported (45). 
 
There are several reports available about decaffeinated coffee intake as one of the potential risk 
factors for RA, especially showing stronger evidence in sero-positive patients. Conversely, it is 
contradictory with another studies that were shown no correlation between 
decaffeinated/caffeinated coffee or tea consumption on disease progression (46-48). 
Interestingly, alcohol intake has shown to have a factorable effect on RA development in a 
Scandinavian cohort study (49). 
 
In general, women are more predisposed to develop an autoimmune disease, including RA. This 
can be partially explained by the changes in the concentrations of female hormones like 
estrogen, testosterone, progesterone and prolactin. During pregnancy the disease onset is 
reduced by 70% and then increased during postpartum period (50, 51). Nevertheless, there is no 
consistent finding of the oral contraceptive use, breast-feeding or hormone replacement therapy 
on disease outcome (52). Thus, identification of environmental risk factors will lead to better 
understanding of disease mechanism and offer a chance to prevent the progression of arthritis in 
high-risk populations. 
 
GENETIC FACTORS IN RHEUMATHOID ARTHRITIS 
RA is a heterogeneous disease, where disease susceptibility can be explained by approximately 
60% of genetic component (22, 23). Monozygotic twins have higher concordance rate (15%) 
compared to dizygotic twins (4%) (22). Identification of the genes that cause RA is not a trivial 
task and despite the enormous efforts, only few genes have been confirmed so far. 
 
MAJOR HISTOCOMPATIBILITY COMPLEX 
The first causative locus correlated with RA was identified by Stastny in 1978 and defined as 
Human Leukocyte Antigen (HLA)-DR that resides in the major histocompatibility complex 
(MHC) class II (53). The association between MHC and RA is so far the strongest link in RA 
and has been replicated independently in many populations. Subsequent analysis revealed that 
several alleles at HLA-DRB1 locus (DRB1*01, DRB1*04) are strongly associated with RA and 
those bear a common sequence or so called “shared epitope” (SE) (54). The sequence has been 
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mapped to the third hypervariable region of DRβ molecule, particularly to amino acids at 
position 70-74 (55). Since, the susceptibility epitope (QKRAA-glutamine-leucine-arginine-
alanine-alanine, QRRAA or RRRAA) is located in the “wall” of the peptide-binding groove, it 
can influence the biding and presentation of the specific arthritogenic peptides by HLA-DR 
molecule to T cells and thus might trigger the autoimmune response. It has been shown that 
shared epitope can influence the severity of the RA and it is more pronounced in the patients 
carrying the homozygosity (56).  Several another genes in the MHC locus have also been 
identified as additional risk factors independent of HLA-DRB1 allele (57). It is important to 
note that HLA genes account approximately for 30% of the heritable risk, which leave the room 
for identification of unknown non-HLA genes. Only less than ten years ago, due to 
development of advanced SNP genotyping technology (chips containing 1,000,000 SNPs), it 
was possible to genotype large patient’s cohorts within feasible time and cost limits.  
 
Recently, genome wide analysis studies (GWAS) reveal numerous genes located outside the 
MHC region. Among them, Protein tyrosine phosphatase non-receptor type 22 (PTPN22), 
Tumor necrosis factor receptor-associated factor 1, complement component 5 (TRAF1-C5), 
Peptidylarginine deiminases citrullinating enzyme 4 (PADI4), signal transducer and activator of 
transcription 4 (STAT4), Fcγ receptors (FCGR) are the most associated genes with RA and 
will be discussed in detailed below.  
 
PTPN22 
The gene PTPN22, also known as “Lyp”, has been at first associated with T1D (type 1 diabetes) 
and shortly thereafter with RA (58). PTPN22 plays an important role in T-cell receptor 
signalling since Lyp together with Csk (regulatory kinase) down-regulate T cell activation (59, 
60). Surprisingly, R620W missense polymorphism in PTPN22 causes gain of function activity 
and renders the Lyp more potent suppressor of early T cell development (61). This might cause 
failures during T cell selection process in the thymus as well as moderate the activity of Tregs 
(60, 62). Genetic risk factors have a tendency to overlap with different autoimmune disorders, 
hence the risk variant of PTPN22 has also been associated with systemic lupus erythematosus 
(SLE), Graves’ disease and juvenile idiopathic arthritis (61) as well. Recently, it was shown that 
polymorphism in PTPN22 can altered the faction of B cells as well.  
 
 15 
TRAF1-C5 
The TRAF1-C5 has been linked with RA in North American/Swedish genome-wide association 
studies as well as in a candidate gene approach investigated by Dutch group, which was 
confirmed by many others as well (63-66). C5 encodes the complement component 5 and its 
cleavage product C5a is a potent chemoattractant that can mobilize synovial and inflammatory 
cells and thus play the critical role in articular inflammation. In detail, this will be discussed in 
the section of “Genetic basis of arthritis”. Tumor necrosis factor (TNF) receptor-associated 
factor 1 (TRAF1) plays a crucial role in cell proliferation and differentiation. The most strongly 
associated SNPs (rs3761847 in GWAS, rs10818488 in candidate gene approach) are located in 
an intergenic region of chromosome 9 between TRAF1 and C5 gene and increase the 
susceptibility and severity of anti-CCP positive RA (63). On the other hand, recently published 
data by Han et al., strongly suggest that only TRAF1 but not C5, is RA risk causative gene (67, 
68).  Furthermore, difference in RA susceptibility was 45 fold increased in patients carrying all 
three (HLA-SE, PTPN22, TRAF1) highest risk variants (68).  This kind of analysis might 
establish individual prognosis for RA development leading to more accurate therapy. Another 
study has shown TRAF1-C5 association with SLE (69).  
 
STAT4, CTLA4, CD40 
Association of STAT4 with RA has been confirmed in both Caucasian and Asian populations 
(70-72). Additionally, the STAT4 risk haplotype was also associated with SLE (70). STAT4 is 
a key immune-regulator in cellular response to IL-12 and IL-23. Once it is activated via these 
cytokine receptors, it translocates to the nucleus and leads to transcription of IFN-γ. It plays role 
in the development of Th1 responses and expansion of Th17 cells (73).  STAT4 is a potential 
therapeutic target, since its expression level is diminished after DMARDs treatment (74).  
 
CTLA4, expressed on the surface of Th cells, belongs to the same family as CD28 and binds to 
CD80/86 on APC cells. Several studies have reported its role in multiple autoimmune disorders 
(75, 76). However, only modest association with RA has been found (77). Two important 
findings strengthen its influence in RA susceptibility. First, beneficial treatment of RA with 
antibodies neutralizing CTLA4 activity (78), and second that CTLA4 risk allele enhanced the 
development of ACPA-positive RA (79).  
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Role of CD40 has been confirmed and replicated in two independent studies (80, 81). It has 
been reported to be a genetic risk factor that might influence the RA severity and the common 
risk haplotype might be important for the rate of joint destruction in ACPA-positive RA patients 
(81).  
 
PADI4 
It is one of the isoenzymes that are involved in the process of posttranslational modification 
(citrullination) of arginine residues to citrulline, which subsequently may lead to the production 
of anti-CCP antibodies. First it was suggested to be associated with RA susceptibility in 
Japanese population, where causative SNPs affect the stability of the transcript (82) and soon 
after replicated by others (83). However, the conflicting results in European descent have been 
reported (84, 85). 
 
FCGR 
The FcγRs are receptors for the Fc region of immunoglobulin G (IgG). Since majority of RA 
patients are sero-positive (ACPA, RF) and IgG-immune complexes are present in their synovial 
fluid, it was proposed that FcγRs might have an important role in disease pathogenesis. The 
interaction between immune complexes and FcγRs activates macrophages within the joint 
leading to release of chemokines, cytokines and pro-inflammatory mediators that mediates 
cartilage breakdown(86). In humans three major FcγRs subclasses are present: high-affinity 
FcγRI (CD64) and two low-affinity FcγRII and FcγRIII (CD32 and CD16 respectively).  
 
The low-affinity receptors are encoded by the cluster of five FCGR genes located on the 
chromosome 1q23.3:  FCGR2A, FCGR3A, FCGR2C, FCGR3B and FCGR2B (from 
centromere to telomere).  Several studies have implicated the common functional SNP in 
FCGR3A that confers phenylalanine (F) to valine (V) at position 158 in the immunoglobulin-
binding domain, which as a functional impact. Polymorphism in FCGR3A gene affects the 
binding affinity of the receptor to IgG, in the way that V158 haplotype increases affinity to IgG 
more than F158 haplotype. Consequently, more potent capture of IgG immune complexes may 
influence efficient presentation of arthritogenic antigens. Moreover, the FCGR3A-158V 
homozygosity was associated with twofold increased risk for RA in UK, North-Indian and 
Pakistan populations (87) and may confer the risk for autoantibody positive RA (88, 89). 
However, conflicting results from other groups have been reported (90), indicating ethnicity 
 17 
divergence. Interestingly, there is high sequence similarity between all the five low-affinity 
FCGRs genes, which is most likely due to segmental duplications. One of the good examples is 
98% sequence homology between FCGR3B and FCGR3A gene (91). Fascinatingly, the copy 
number variable (CNV) regions in FCGR locus have been linked to SLE (92-94). CNV can 
modify the receptor expression and binding ability of immune complexes. To this extent, 
presence of variable copy number of FCGR3B gene influences the expression level of receptor 
on the cell surface.  In the studies presented by Robinson et al., deletions of FCGR3B was 
associated with lower phagocytosis and therefore reduced clearance of immune complexes 
especially in ACPA positive patients. Since FcγRIIIb is mostly expressed on neutrophils, its 
role in RA pathology was further strengthened (95). Existence of copy number variations and 
single nucleotide polymorphisms in low- affinity FCGR locus reveal the genetic complexity 
and need for the development of new technology strategies.   
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ANIMAL MODELS OF AUTOIMMUNE DISEASES 
Rheumatoid arthritis is a heterogeneous disease where complex genetic factors and 
environmental elements interact with each other and participate in disease pathogenesis and 
progression. Complexity of the disease including different ethnicity, lifestyle, and various 
treatments of investigated populations and ethical reasons confer limitations for finding new 
genes driving autoimmunity and the underlying mechanisms. Therefore utilization of animal 
models became crucial. Although there is no single animal model that can completely 
recapitulate the multifactorial human disease like RA, there are already several models for 
arthritis available that provide the opportunity to analyse different disease phenotypes.  Usually, 
animal models for autoimmune diseases are conducted in rodents due to their smaller sizes, 
large number generations per year, relatively big number of offsprings (strain dependent) and 
the most importantly the possibility of genetic alterations (knock-in, knock-out, transgenic 
strains) and, the chance for controlled environment. Therefore animal models provide an 
excellent opportunity to progress/improve our knowledge about molecular mechanisms of 
candidate genes as well to find new, successful therapeutics. Currently, several spontaneous and 
induced animals models for autoimmune diseases are available. It is important to note that 
arthritis in rodents might be induced by inoculation with various joint-specific antigens/cartilage 
components such as type II collagen (CIA), cartilage oligomeric protein (COMP), proteoglycan 
(PG), type IX collagen, type XI collagen, as well as oils (adjuvants), microbial products or 
antibodies (96). Some of the models that are relevant to my thesis will be presented in more 
detail below. Other broadly used models for arthritis include spontaneous models such as TNF-
α transgenic mouse, K/BxN mouse and SKG mouse. Briefly, SKG model is environmental 
dependent and is absent in germ-free animal house. However, it can be induced by injection of 
zymosan in a Dectin-1 dependent manner (97). Susceptibility of SKG mice to arthritis is due to 
a mutation in ZAP 70 gene that alters the thymic T-cell selection (98). TNF-α transgenic mouse 
over expressing human TNF -α develops chronic, progressive polyarthritis and the 
administration of monoclonal antibodies against human TNF-α completely abrogates the 
disease. This model is particularly useful for evaluating the efficiency of novel therapies in RA 
(99).  
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COLLAGEN-INDUCED ARTHRITIS 
Collagen-induced arthritis (CIA) is the most commonly used animal model that in many 
features resemble RA (100) and thus a preferred pre-clinical model for rheumatoid arthritis. It is 
induced by an intradermal immunization with collagen type II (CII) emulsified together with 
adjuvant, at the base of the tail. Clinical signs of disease typically occur approximately three to 
five weeks after initial immunization and histologically are characterized by infiltration of 
inflammatory cells, synovial hyperplasia, bone and cartilage erosion. The clinical picture of 
mice with arthritis is represented by swollen and reddish paws. CIA can be induced in many 
species including mice, rats and non-human primates (101, 102). Collagen is one the most 
abundant protein in the body and so far 28 types of collagen have been described. However 
90% of collagens in the body are type I. Collagen type II is the major component of the joint 
cartilage and jelly-like substance that fills the eyeball (vitreous humour). It is synthesised by 
chondrocytes and composed of three α1(II)-chains that form triple helix. During CII 
biosynthesis posttranslational modification like hydroxylation and glycosylation occur (103).  
Similar to humans, the MHC encoding genes are important for CIA development. All the 
susceptible strains are predisposed to CIA due to the expression of MHC class II haplotypes H-
2q or H-2r.  By using the transgenic mice, the susceptible gene within the MHC region (called 
Aq) has been identified (104).  The Aq molecule presents the immuno-dominant T cell epitope 
of CII (256-270) glycopeptide that confers susceptibility to CIA (105). CIA can be induced in 
predisposed strains with collagen of different origins, H-2q haplotype strains are susceptible to 
autologous (mouse) or heterologous (rat, chick, bovine, human) type II collagen immunization 
(106, 107). The CIA induced by homologous collagen causes more chronic arthritic disease 
(107). Furthermore, H-2r and H-2b haplotype bearing mice develop arthritis upon immunization 
only with bovine collagen. The same sequence of immunodominant CII epitope (CII256-270) is 
shared between rats, human, chicken, and bovine species but vary with one amino acid at 
position 266 (aspartic acid instead of glutamic acid) in mouse that alters peptide recognition and 
affinity binding (108). This finding indicates why heterologous CII peptides induce more severe 
disease than mouse CII. In paper II we have used CII of three different origins: chicken, rat and 
bovine for immunization of the heterogeneous stock mice. It is important to stress that several 
other non-MHC related loci controlling CIA susceptibility in mice have also been found, such 
as Ncf1, C5 and FcγR cluster of genes.  
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Discovery of the non-MHC gene, Ncf1 regulating arthritis has shown the advantage of 
utilization of animal models in the detection of the genes with a small effect. Ncf1 gene encodes 
the p47phox protein, a subunit of phagocytic nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidative complex. At first, it was positionally cloned using pristine-induced arthritis 
model in rats (109). DA rats showed lower production of reactive oxygen species (ROS) and 
developed a more severe arthritis compared to E3 strain. Similar results were replicated in 
mouse strain with a spontaneously occurred Ncf1 gene mutation (110).  Recently, the causative 
SNP that impairs the function of Ncf1 gene in DA rats has been mapped (111). Thus, reduced 
ROS production increases the severity of arthritis followed by an elevated titre of antibodies 
and the production of pro-inflammatory cytokines. In the paper V we have investigated whether 
the influence of mutated Ncf1 gene on arthritis severity is independent of classical adjuvant.  
 
COLLAGEN ANTIBODY INDUCED ARTHRITIS 
As mentioned before, RA is associated with autoantibody production against self-proteins such 
as CII, citrullinated proteins (ACPA) or IgG (RF).  The role of autoantibodies in disease 
pathology was highlighted by the fact that serum taken from arthritic mouse that has been 
immunized with CII or from a RA patient can induce arthritis in non-immunized recipient (112, 
113). Moreover, arthritis can be also be induced in naïve mouse by transfer of a cocktail or with 
a single mAb pre-formed anti-collagen monoclonal antibodies, so called CAIA (collagen 
antibody induced arthritis) (114-116). The first clinical sings of arthritis in antibody transfer 
model appears within 24-48h after the antibody administration and they resemble acute phase of 
CIA. In contrast to CIA, CAIA model is transient and usually mice after one month became 
normal again. To enhance the severity and incidence of CAIA, single injection of 
lipopolysaccharide (LPS) is used. Disease susceptibility is MHC independent (112, 114).  
Moreover, CAIA can be induced in the absence of either T cells or B cells indicating no 
influence from adaptive immune system. On the other hand T and B cell knockout mice 
develop less severe arthritis, which implies regulatory effect of these cells (117). Requirement 
of neutrophils and macrophages is essential for the disease development (118) as well as 
complement proteins and FcγRs. CAIA model is highly reproducible and provide valuable 
information about the effectors phase of arthritis without involving the priming pathway. This 
model reflects the contribution of humoral immunity in the development of arthritis. 
Monoclonal antibodies used in this thesis were previously characterized and they are presented 
on the Figure 1. 
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Figure 1. Monoclonal antibodies used in arthritis experiments for this thesis 
 
 
GLUCOSE-6-PHOSPHATE ISOMERASE INDUCED ARTHRITIS 
Glucose-6-phosphate isomerase (G6PI) is an enzyme of the Krebs cycle and is ubiquitously 
express in the body. More than 15 years ago, by chance Kouskoff et al (119) have discovered a 
new model of spontaneous arthritis, so called K/BxN model. It was found in the cross of bovine 
ribonuclease specific T- cell receptor transgenic C57BL/6 mouse with the H2g7 carrying NOD 
mouse. The offsprings developed severe and destructive arthritis with the production of high 
titter of G6PI-specific antibodies (120). Since then research has turned towards understanding 
the role of G6PI in arthritis development. However, it was still mysterious why response to a 
universal glycolytic enzyme is so joint specific. Further studies revealed that arthritis might be 
induced by injection of serum from arthritic mice or by immunization with human G6PI protein 
as well as with human G6PI325-339 peptide (121-123). This model is dependent on the presence 
of T-cells, B-cells, and complement components as well as FcγR effector cells. In paper II, we 
have investigated if heterogeneous stock mice are sensitive for arthritis induced by recombinant 
G6PI.  
 
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
Experimental autoimmune encephalomyelitis (EAE) is largely used an experimental animal 
model that mimics human multiple sclerosis (MS). EAE can be induced in many species 
including rat, mouse, guinea pig, rabbit and monkeys. EAE can be induced actively by 
immunization with the emulsion consisting of one of the following antigens: purified myelin, 
spinal cord homogenate (SCH – paper II), myelin proteins or peptides: myelin basic protein 
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(MBP), proteolipid protein (PLP), oligodendrocyte protein (MOG – paper II) and adjuvant 
usually CFA and followed with injections of two doses of pertussis toxin that allows to open the 
brain-blood barrier. The passive induction of EAE may be achieved with an adoptive transfer of 
encephalitogenic T cells. EAE is a T-cell mediated autoimmune disorder since B cell knockout 
mice can develop severe EAE. However the role of B cells in EAE pathogenesis is elusive due 
to their dualism. B cells produce autoantibody binding to myelin antigens leading to destruction 
of the nervous system but they could also play a regulatory role during the recovery phase. First 
symptoms of the disease appear few days after the immunization and they are recognized by tail 
weakness following by successive paralysis of the body starting from hind limbs, front limbs 
leading to tetra paralysis that may eventually cause death. 
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FCγ RECEPTORS 
So far four FcγRs have been described in mouse genome: FcγRI (CD64), FcγRIIb (CD32) and 
FcγRIII (CD16) and the recently discovered FcγRIV that can be divided into two major classes: 
activating (FcγRI, FcγRIII, FcγRIV) and inhibitory (FcγRIIb). On the basis of sequence 
similarity in extracellular domain of mouse and human receptors, FcγRI are orthologous, as the 
same applied for FcγRIIb, whereas FcγRIII seems to be an orthologue with human FcγRIIA, 
while FcγRIV was proposed to be an orthologue with human FcγRIIIA. Both human and mouse 
FcγRs are the result of duplications and diversification and are characterized by high sequence 
homology. Similar to human, mouse FcγRs are present on chromosome 1 (except the FcγRI in 
chromosome 3) and are located in close distance to each other, the so-called a cluster region in 
proximity to the family of the FcR-like genes. The work in this thesis is focused on the mouse 
low-affinity receptors (FcγRIIb, FcγRIII, FcγRIV) and they will be described in greater detail. 
 
STRUCTURE OF FCγRS 
All FcγRs are glycoproteins. Majority of FcγRs (FcγRII, FcγRIII, FcγRIV) have two C2-type 
extracellular Ig domains whereas FcγRI consist one additional domain, which was claimed to 
drive the high-affinity binding of this receptor (124). The extracellular part of Fc receptors 
shows high sequence similarities but they differ in their transmembrane and intracellular 
domains, which are responsible for intracellular signalling. Only one of the two extracellular 
domains of FcγR is in contact with Fc part of IgG (125) and thus the interaction of FcγR-IgG is 
in 1:1 stoichiometry (126). FcγRIIb contains an immunoreceptor tyrosine-based inhibitory motif 
(ITIM) whereas FcγRIII and FcγRIV contain immunoreceptor tyrosine-based activatory motif 
(ITAM) in the intracellular domain. The activating FcγRs are dimmers consist of a ligand-
binding α-chain and the common γ-chain (carrying ITAM motif) while inhibitory FcγRIIb is a 
single chain receptor (127). The common γ-chain plays an important role not only in passing on 
the activating signals but also as an essential mediator in the expression of activating FcγRs and 
thus FcγRI, FcγRIII and FcγRIV are dependent on this receptor subunit expression for 
activation. Deletion of the common γ-chain leads to loss of function of all the activating 
receptors. Moreover loss of function in other unrelated Fc receptor proteins have also been 
described (128). Studies using γ-chain knockout animals revealed impaired antibody–mediated 
effector mechanisms, like phagocytosis of immune complexes (ICs) and ADCC.  
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SPECIFICITY, AFFINITY AND DISTRIBUTION 
The harmonious expression of inhibitory and activating receptors on the same cell is important 
for the creation a balanced immune response. Furthermore, recent studies have highlighted the 
divergent roles of FcγRs depending on their affinity to IgG subclasses. With the exception of 
the FcγRI that binds with a high affinity (107-109 M-1) both monomeric IgG as well as IgG 
molecules in the form of immune complexes, the remaining activating FcγRIII and FcγRIV and 
inhibitory FcγRIIb receptors have lower binding affinities (106-107 M-1) and bind mainly ICs 
(129). Despite containing the low affinity receptors to IgG, the cell, which expresses numerous 
FcγRs are in fact has high avidity to IgG-opsonised pathogen. There are four different IgG 
subclasses in mice: IgG1, IgG2a, IgG2b, IgG3 that have diverse binding affinities for the 
activating and inhibitory FcγRs. Better understanding of the efficacy of the IgG subclasses in 
mediating the immune response was made by determining the A/I ratio, the ratio of affinities of 
a given IgG subclasses for activating FcγRs to inhibitory FcγRIIb (130). For example IgG1 has 
the lowest A/I ratio of 0.1, indicating that function of this isotype is severely regulated by 
FcγRIIb. The FcγRs are widely expressed on the haematopoietic system.  
 
 
Figure 2. Mouse Fc receptors for IgG, expression and ligands (based on (130-133)). 
 
 
Macrophages and monocytes express both inhibitory and activating receptors, whereas DCs 
express mainly FcγRI, FcγRIV, and FcγRIIb, whereas neutrophils dominantly express FcγRIII 
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and FcγRIV and inhibitory FcγRIIb. The are two unique cell types that exclusively express just 
one type of FcγRs, they are NK cells that express activating FcγRIII and B cells that express 
FcγRIIb. The summary of this paragraph is presented in Figure 2.  
 
NATURAL POLYMORPHISM IN MOUSE FCγRS GENES 
Functional imbalances in the activating and inhibitory Fc receptors due to genetic variations 
predispose to the development of autoimmune disorders. Several autoimmune-prone inbred 
mouse strains such as MRL, NZB, BXSB, 129, NOD carry the polymorphism in promotor 
region of FcγRIIb that reduces the expression level of the receptor on B cells and macrophages 
(134, 135). Moreover, the polymorphism in FcγRIIb resulting in two variants of Ly17.1 and 
Ly17.2 has been described. However there is no evidence that this coding region polymorphism 
influences the receptor functions (136). In addition FcγRIII exists in three different haplotypes: 
FcγRIII:V, FcγRIII:H and FcγRIII:T. It was shown that mice that carry the FcγRIII:H haplotype 
are more susceptible to arthritis than mice with FcγRIII:V haplotype (137). Comparison of FcγR 
polymorphisms occurring in NOD and B10.Q strains are presented in Table 1.  
 
Table 1.  The summary of known polymorphisms in NOD and B10.Q strains (133, 137, 143-
145). 
Additionally, by using knockout approaches, it is possible to elucidate the contribution of each 
of the FcγR in autoimmune disorders. For example, FcγRIIb deficiency renders normally 
resistant H-2b strain of mice susceptible to CIA (138). Moreover, FcγRIIb knockout mice 
showed increased susceptibility to CAIA (115) and they are predisposed to develop 
spontaneous hypergammaglobulinemia, production of anti-chromatin antibodies(139) and 
impaired removal of immune-complexes resulting in severe glomerulonephritis mimicking 
human SLE(140). On the other hand mice that are deficient in common γ-chain or in FcγRIII 
Receptor NOD B10.Q 
FcγRIIb Ly 17.1 
Deletions in the promotor region 
Ly17.2 
FcγRIII H:haplo T:haplo 
FcγRIV Ile57 Thr57 
 26 
are highly resistant to CIA, even though anti-CII Ab production is comparatively normal in 
these mice(141, 142).   
 
FEEDBACK REGULATION 
The inhibitory FcγRIIb is the most abundantly expressed FcγR. It is present on all leukocytes, 
except T cells and NK cells (Figure 2) and exists in two different forms: FcγRIIb-1 and 
FcγRIIb-2. The FcγRIIb-1 is solely expressed by B cells whereas FcγRIIb-2 is found on 
remaining cell populations and has the ability to induce endocytosis or phagocytosis via 
receptor cross-linking. Thus, FcγRIIb plays an important role as the negative regulator in innate 
and adaptive immune responses. FcγRIIb expression level seems to be setting the threshold 
level for B cell activation. Additionally, it acts as the checkpoint during later peripheral B cell 
development, including the exclusion of low-affinity autoreactive B cells (146), preventing the 
expansion of IgG positive auto-reactive plasma cells. Furthermore, it has been suggested that 
FcγRIIb can also regulate the plasma cell survival and apoptosis. The FcγRIIb is highly 
expressed on terminally differentiated plasma cells, but BCR expression is very low or absent. 
Apoptotic signal of plasma cell is triggered by FcγRIIb upon cross-linking with the immune 
complexes. Interestingly, autoimmune-prone mice, which have significantly reduced level of 
FcγRIIb, are protected from apoptosis. Hence, the failure in plasma cell survival may influence 
their higher abundance (147, 148). As mentioned before, the FcγRIIb is expressed widely on 
innate immune effector cells (mast cells, granulocytes, macrophages) and controls their 
antibody-mediated responses such as phagocytosis, antibody-dependent cellular cytotoxicity 
(ADCC) and release of pro-inflammatory mediators. However, its negative regulation is strictly 
dependent on the IgG isotype bound to the inhibitory receptor and is determined by already 
described A/I ratio. Another crucial function of inhibitory receptor is the regulation of DC 
activation and maturation. Several groups have already described the role of immune complexes 
bound to DC as an enhancing factor in antigen presentation process (149, 150). In addition, 
expression of FcγRIIB on DC regulates immune-complex mediated maturation, which was 
exemplified by spontaneous maturation of DCs derived from FcγRIIb deficient mice (151). 
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COMPLEMENT SYSTEM 
Complement system is a key component of innate immunity contributing to inflammation but it 
also plays an immuno-regulatory role in the modulation of adaptive immune responses (152, 
153). Complement can be activated by three different pathways: classical, mannose-binding 
lectin and alternative that are depicted on Figure 3. Complement system consists more than 30 
plasma and cell surface-associated proteins (154), which are constitutively synthesized in the 
liver and secreted into the circulation. However, pro-inflammatory cytokines like IL-6, TNF-α 
or IFN-γ stimulate the production of complement components in the macrophages(155, 156). 
Activation of the complement proteins occurs through the catalytic cascade where the activation 
of one protein leads to the proteolytic cleavage of the next resulting in the amplification of the 
signal. Once the cascade is activated, complement components can be involved in opsonizing 
the invading pathogens and tagging them for phagocytosis (C3b, C4b), attracting the leukocytes 
(C3a, C5a) or direct killing the invaders through the assembly of membrane attack complex 
(MAC, C5b-C9). Moreover, it has a crucial role in the clearance of immune-complexes (C3b 
and C4b). Thus, lack of C3 protein may lead to accumulation of immune complexes in the 
tissue, which subsequently can cause inflammation. C3a and C5a are very potent chemo-
attractants that can recruit neutrophils, phagocytes and eosinophils to the site of inflammation, 
stimulate the production of pro-inflammatory molecules and enhance vascular permeability 
(157-159). Furthermore, anaphylatoxins like C5a and C3a play a crucial role in de-granulation 
of the mast cells, eosinophils and basophils. Since the activation of complement cascade is rapid 
in action, it needs to be tightly controlled; therefore various plasma soluble/membrane-bound 
complement inhibitors are present in the host to protect the tissue from destruction (160). 
 
ROLE OF COMPLEMENT IN RA 
Contribution of complement to the development of inflammatory diseases such as acute 
respiratory distress syndrome (163), sepsis (164), glomerulonephritis (165), asthma (166) and 
rheumatoid arthritis (167) have been described. The common feature of these diseases is 
accumulation of neutrophils that have been attracted by the anaphylatoxin, C5a. Activation of 
neutrophils triggered by binding of C5a to C5aR cause the release of reactive oxygen species 
(ROS) that subsequently may lead to tissue damage. Moreover, it was shown by Shushakova et 
al (168) that C5a can modulate the expression level of both FcγRIII and FcγRIIb and thus 
enhance the autoimmune response. As mentioned before, RA is characterized by elevated levels 
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of immune complexes (169) that may potentially activate the complement proteins. Indeed, 
there are ample evidences of complement activation in synovial fluid of patients with RA. 
Furthermore, increased consumption of C3 and C4 (170) as well as high concentrations of 
anaphylatoxins C3a and C5a in synovial fluid of RA patients have been reported (171, 172). It 
is not only the increased activation of complement components but also their deficiency is 
associated with more pronounce inflammation (160, 173). Hence, damage of the tissue caused 
by complement than the complement activation itself is the key factor in the manifestation of 
many diseases.  
 
Figure 3. Simplified scheme of activation pathways of complement system and its inhibitors 
(Based on (161, 162)). 
 
To date, it is still under debate, which pathway of complement activation is more relevant in 
RA. The possibility of alternative pathway as the main trigger could be explained by the 
elevated concentrations of Bb fragment present in the synovial fluid of RA patients. On the 
other hand, classical pathway may be triggered through the binding of various immune 
complexes present in the serum and synovial fluids of RA patients (174). However, the 
contribution of the lectin pathway to RA is not conclusive (175, 176).  
 
ROLE OF COMPLEMENT IN ANIMAL MODELS 
The role of complement in arthritis can be determined by utilization of genetically modified 
animals.  It was shown that C3 or factor B knockout mice are partially resistant to CIA (177), 
 29 
which indicate that both the classical and alternative pathways are likely to be involved in 
arthritis. However, Banda et al (178) have shown that only alternative but not classical pathway 
has a major impact on CIA development. Thus, importance of both pathways in CIA is not yet 
clear. Furthermore, C3 and factor B deficient mice developed less severe arthritis with delayed 
onset after injection with anti-collagen monoclonal antibodies (179). In relation to C5 protein, 
deficiency or administration of neutralizing antibodies prevent CIA and ameliorates already 
established disease (180, 181). In paper IV we have shown that Cia2 congenic line that is 
deficient in C5 is resistant to CAIA and CIA development. The Cia2 locus has been also 
identified in the F2 cross between DBA/1 and SWR/J strain (182). The deficiency in SWR/J 
and NOD strain is cause by 2bp deletion in exon near the 5’end of the Hc gene that results in 
the frame-shift and early termination causing C5 deficiency (183). Furthermore, the importance 
of complement components was linked with spontaneous K/BxN arthritis model. Utilization of 
different crossing of K/BxN and knockout mice for various components revealed that this 
model is dependent on alternative pathway and the tissue destruction is not due to MAC 
assembly (184). Moreover, C3 depletion by cobra venom factor results in diminish antibody 
response and therefore complement system has been shown to have regulatory function on 
humoral immune response.  
 
SYNTHESIS OF COMPLEMENTS COMPONENTS 
The most of complement components are synthesized by hepatocytes. However, it has been 
shown by Brodeur et al (174) that synthesis of complement factors can occur also within 
rheumatoid synovium. In fact all the normal tissues are able to produce at least one component 
of the complement system (185). All different cell types have been shown to synthesize 
complement components including fibroblast, phagocytes, endothelial cells, alveolar type II 
epithelial cells and adipocytes (186, 187). It was demonstrated that cells of synovial membrane 
(particularly fibroblast, phagocytes, endothelium) could produce complement components C2, 
C3, C4 and C5. In another study, using in situ hybridization method, increased expression of 
mRNA for factor B, C3, C3aR and C5aR in synovial tissue of RA patients was reported (188). 
This data suggests that during inflammatory conditions like RA, complement components are 
rather produced locally in the synovium than derived from plasma. However, our findings using 
bone marrow transfer experiment showed that liver could be the main source of complement C5 
even under inflammatory conditions (paper IV).   
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IDENTIFICATION OF GENES 
Identification of genes involved in the disease pathogenesis is tedious and complex both in 
humans as well as in animal models. One of the advantages of using animal models is the 
possibility to identify genes with small effects compared to mapping them in human studies. 
Moreover the animal’s genome can be modulated. Therefore animal models provide the 
excellent tool to gain the knowledge about mechanism and pathways leading to disease 
development. Identification of the genes consists of two steps. Initially, two or more strains that 
differ genetically in respect to the investigated trait are being crossed and linkage analysis that 
correlates the complex phenotypes to specific regions of chromosomes, quantitative trait loci 
(QTL) is being applied.  The next step aimed to narrow down the chromosomal region to the 
smallest size as much as possible, ideally containing only one gene, which is called positional 
cloning.  Since this is almost impossible to achieve (for example FcγRs cluster region in paper 
III), one needs to find a specific phenotype for the gene such as functional assays or knockout 
animals (189).  
 
INBRED STRAINS 
First inbred strain, DBA was created by C.C Little in early twentieth century. Inbred strains are 
made by sister-brother mating for more than 20 generations resulting the mice being as much 
alike as possible and carrying around >99% of homozygosity at all the loci.  Although there are 
more that 450 inbred stains available, only those well characterized are used in experiments. 
Each inbred strain has unique sets of characteristics that differ from all other inbred strains. 
They are often selected for their specific phenotypes, for example C57BL/6 has increased 
preferences for narcotics and alcohol, whereas 129 strain is widely used in transgenic 
technology (190-192). Therefore inbred strains provide valuable tools for developing animal 
models for human diseases.  
 
INTERCROSSES AND BACKCROSSES 
The most common way to achieve the identification of the disease-causative genes is to cross 
two inbred strains that represent diverse phenotypes. The first cross generates F1 offspring 
where all the animals are genetically similar and heterozygous for all the loci. Then, F1 
individuals can be either intercrossed (F2) or backcrossed with one of the parental inbred strain 
(N2). Now, the genome is shuffled and chromosomes have mosaic structures containing the 
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fragments inherited from both the parental strains. The F2 generation provides the information 
of disease fashion (recessive, additive, dominant) whereas N2 generation is more powerful in 
detection of dominant genes (189). Both animals of F2 or N2 generations carry unique 
genotypes due to recombination. For that reason, all animals need to be phenotyped as well as 
genotyped. Several types of markers can be used, including single nucleotide polymorphisms 
(SNPs) or simple sequence repeats (SSRs or microsatellites).  Usually, QTL detection is 
performed by genome scan with 100 markers (193). Two-generation crosses have been used to 
detect most of the CIA loci. The Cia2 and Cia9 loci earlier investigated and further studied in 
this thesis were identified in crosses between arthritis resistant strain – NOD and the 
intermediate susceptible strain – B10.Q (194).  
 
CONGENIC STRAINS 
Since, identified QTL contains hundreds of genes and it is unlikely to pinpoint the disease-
causative gene at this stage. Therefore, the next step is to isolate the QTL into congenic strain. 
This is obtained by backcrossing of the desired QTL to the background strain for more that 10 
generations resulting in 99.9% purity of the recipient genome. Congenic strain has either a 
chromosome region from disease-resistant strain that replace the same region from a susceptible 
strain (Cia2 and Cia9 congenic strains described in papers III and IV) or reciprocally when the 
disease-susceptible region is introduced in to the resistant background. This process is time 
consuming and it can be shortened by speed congenic approaches, that is based on marker-
assisted genotyping of each offspring and selecting those individuals with the least 
contaminating fragments from the donor genome. The number of backcrossing is strictly 
dependent on the number of screened individuals and the number of markers used for 
genotyping. With speed congenic technique, it is possible to shorten the time to six backcross 
generations.  Each backcross generation needs to be phenotyped to confirm the presence of 
investigated QTL. Once the congenic strain is “ready”, the locus can then be further dissected 
into smaller sub-congenic lines and characterized. Therefore testing the sub-congenic lines for 
disease susceptibility will help to reduce the size of the causative interval and hopefully 
pinpoint the gene. The strategy of generation of sub-congenic lines used in Cia9 project and 
testing mice with several smaller overlapping gene regions/intervals made us possible to 
exclude big parts of the original locus.  
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HETEROGENOUS STOCK MICE 
Heterogeneous stock cross is an advanced intercross of several inbred strains that have been 
bred for large number of generations and were kept in pseudo-random breeding scheme to 
achieve high density of recombinations in each individual. In the present investigation, we used 
Northport HS stock mice that was generated by crossing eight inbred progenitor strains: A/J, 
AKR/J, BALB/CJ, LP/J, CBA/2J, C3H/HeJ, C57BL/6J and DBA/2J for more than 55 
generations, which resulted in mosaic structure of each chromosome. The average distance 
between the recombinations is less than 2 cM (195), which allows for high resolution mapping 
of small-effect QTLs (195-197). However, the high level of recombination requires high 
number of markers that need to be very closely spaced for genotyping and the use of a robust 
statistical method (HAPPY). In order to use the HS cross for genome wide locus identification, 
large number of animals are required due to increased number of alleles and higher variability 
in the HS population. In paper II, HS mice were screened for susceptibility to autoimmune 
disease models like arthritis (CAIA, CIA, GPI-induced arthritis) and EAE induced by spinal 
cord homogenate of different origins or MOG peptide. It is clear that to be able to induce CIA 
in HS stock, arthritis prone MHC H2q haplotype needs to be introduced. Therefore, HS stock 
animals were crossed with C57Bl/10Q (B10.Q) mice. In paper I, we used more than 1700 HS x 
BQ mice to study CIA development. All the mice were phenotyped, genotyped and analyzed in 
detail. As a result, we were able to find 18 new loci as well as fine mapped several already 
known loci like Cia9 (paper III) and Cia2 (paper IV). 
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“SMART POLYMERS” AS ADJUVANTS 
As described above, most of animal models for autoimmune diseases use either adjuvant alone 
or in the formulation with an antigen to induce disease. Usually, the antigens are emulsified in 
mineral oil with or without mycobacterium, called as CFA (complete Freund adjuvant) or IFA 
(incomplete Freund adjuvant) respectively. The pathogen-associated molecular patterns 
(PAMPs) present on the mycobacterium or other bacterium derivatives can be recognized by 
pathogen-recognition receptors (PRPs) like Toll-like receptors (TLRs) expressed on the 
antigen-presenting cells (APC) (198). Addition of an adjuvant in an immunization emulgate 
enhances, modulates, generates long-lasting antigen depots and sustains the immune response 
against the antigen. However, they have strong ability to distort the immunological mechanisms 
and thus the real response to the self-antigen can be misinterpreted. In additions, some of the 
adjuvants contain toxic compounds. Therefore searching for adjuvants that are able to modulate 
immune response in a more controlled way and allow us to study the actual immune responses 
are in great need.  Recently the interest of synthetic functional polymers has been highlighted. 
These polymers posses a unique feature to respond to a change in environment like temperature, 
pH, electric or magnetic field. They are called  “stimulus responsive” or “smart polymers” 
(199).  
 
 
Figure 4. Schematic picture of interactions between the thermo-responsive PNiPAAm and CII 
(Adapted from Shakya et al (200)). 
 
Smart polymers undergo reversible changes in microstructure from hydrophilic to a 
hydrophobic state. In the macroscopic view, it will be visible, as a precipitate formation from 
the solution.  For example, one of the thermo-responsive polymers; poly(N-
isopropylacrylamide) PNiPAAm, has a lower critical solution temperature (LCST) of 
precipitation around 32.5°C in solution and changes reversibly from hydrophilic below the 
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critical temperature and hydrophobic above it (Figure4). PNiPAAm is a biocompatible and 
biodegradable polymer. This all attributes of thermo-responsive PNiPAAm have suggested a 
possibility of their use for the formation of colloidal suspension with an antigen. Indeed, Shakya 
et al. (200) has shown that PNiPAAm can act as a polymeric adjuvant in collagen-induced 
arthritis and lead to arthritis development with the induction of CII-specific antibody response 
in all the immunized mice. Mice that developed arthritis after immunization with PNiPAAm-
CII have shown a massive infiltration of the immune cells in the joints and significant damages 
of cartilage and bone structure. Moreover, PNiPAAm-Ova immunization did not skew the 
cytokines response towards any one of T-helper cell populations, suggesting the possibility to 
apply PNiPAAm as a general adjuvant and study the actual immune response to the antigen 
(200). Recently, another synthetic polymer poly(lactide-co-glycolide) PLGA, has been used to 
study the sustained-release of steroidal treatment in adjuvant induced arthritis (201). In the 
paper V, we have further characterized the arthritis induced by CII mixed with the new 
polymeric PNiPAAm adjuvant, including cytokine profile, genetic background, TLRs and Ncf1 
gene influence.  
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PRESENT INVESTIGATIONS 
The papers included in this thesis have focus on identification of QTLs, the gene’s 
polymorphisms and mechanisms that lead to arthritis development. We have used different 
genetic approaches to achieve this complex task.  
 
PAPER I 
Background - In paper I, we have used the heterogeneous stock mice, an advanced intercross 
lines between eight inbreed strains of mice. Since HS mice were crossed for many generations, 
which resulted in grained-mosaic structure of each chromosome, it was possible to map CIA 
QTLs with high resolution.  
Method – To be able to induce CIA in HS cohort, we used the variant of the inbred-outbred 
cross between HS mice and B10.Q mice. Homozygous H2q mice were used to set up 81 
breeding cages that produced 1764 F3 mice. We have used these mice in CIA experiment.  
Results – We identified 26 loci controlling arthritis development involving arthritis incidence, 
severity and time of onset. Among them 18 loci are new. In addition, we were able to fine-map 
several already known loci, including Cia2 and Cia9. Several, of the novel loci contain small 
number of candidate genes and therefore are good starting point for positional cloning efforts. 
Interestingly, for the first time, using both mixed model and single-marker association analysis, 
we could map the Cia2 locus to Hc gene, since all the identified SNPs are within the gene. This 
finding indicates the precision of HS strategy. However, we could not exclude the neighbouring 
gene Traf1 despite the high resolution gene regions in the HS mice. Nevertheless, we could still 
confirm the contribution of Cia9 locus in arthritis with the peak marker situated within the Fc-
receptor cluster.  
Conclusions – The results obtained in this paper suggest that HS strategy can provide an 
excellent opportunity to fine map already known disease loci and also to find novel QTLs in 
complex diseases, such as arthritis.  
 
PAPER II 
Background – The heterogeneous stock mice have proven to be useful in the identification of 
new and fine mapping of already known QTLs. Therefore, in paper II we investigated ordinary 
heterogeneous stock mice for their susceptibility in animal models of different autoimmune 
diseases like arthritis and encephalomyelitis.   
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Method – We screened the Northport HS mice for three models of arthritis: CIA induced with 
collagen of different origin (bovine, rat, chicken), CAIA induced by 4 monoclonal antibodies 
and G6PI induced arthritis. We investigated EAE susceptibility induced either with mouse 
spinal cord homogenate (SCH), rat SCH or MOG.  
Results – We found that HS mice are resistant to arthritis induced with rat and bovine collagen 
as well with G6PI protein. However, very low arthritis incidence after immunization with 
chicken collagen was observed (2 out of 68 mice). Regarding CAIA model, HS mice developed 
arthritis with a high frequency (50%). In addition, we showed that HS mice are prone to EAE 
induced by all three antigens (mSCH, rSCH and MOG).  
Conclusions – From this study we can conclude that HS mice could be useful for identification 
of new QTLs involved in encephalomyelitis as well as at the effector phase of arthritis. 
 
PAPER III  
Background – Results from previous gene segregation experiments between B10.Q 
(intermediate susceptibility to arthritis) and NOD.Q mouse strains (arthritis resistant) identified 
two loci contributing to CIA, one disease-promoting locus (Cia9) on chromosome 1 and 
another disease protective locus (Cia2) on chromosome 2. Later, these gene regions were 
confirmed for their influence on arthritis using backcross experiments. NOD allele at Cia9 locus 
promotes arthritis and the linkage peaked at the location of the FcγR region. In this study, we 
postulated that within the Cia9 locus, Fc gamma receptor cluster might be the causative gene 
region involved in arthritis development.  
Method – To be able to identify the underlining genes, the big (165-175Mbp) Cia9 gene region 
has been split up into smaller sub-congenic regions in various mouse strains to be able to 
localize the genes. Three different overlapping sub-congenic lines were created: Cia9c, Cia9b 
and Cia9i. All sub-congenic mice were tested for susceptibility to arthritis phenotypes using 
CIA and CAIA arthritis models.  
Results – Cia9c congenic line devoid of FcγR cluster genes but contains SLAM locus (173-
175Mbp) showed no influence in arthritis development. Similarly, Cia9b congenic line, which 
cover region (165-172.6 Mbp) above of FcγR cluster, is also not susceptible to either CIA or 
CAIA. Interestingly, Cia9i fragment (170.9-173.4 Mbp), which encloses three Fc gamma 
receptors showed a significant difference in CIA severity and incidence. Similarly, mice having 
Cia9i fragment are also highly susceptible to CAIA induced by four monoclonal antibody 
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cocktail (M2139+CIIC1+UL1+CIIC2). Interestingly, we demonstrated that Cia9i strain showed 
differential IgG subclass dependency in arthritis development. 
Conclusions – This paper demonstrates the importance of dissecting QTL to reveal genetic 
effect of complex traits. This study supports our hypothesis that augmented susceptibility to 
arthritis of Cia9i mice can be due to one or both of FcγRIIb and FcγRIII genes. However more 
functional studies are needed to identify the causative gene.  
 
PAPER IV 
Background – In paper IV we focussed on the arthritis protective Cia2 locus that was found in 
chromosome 2 in the B10.Q x NOD.Q cross. The promising candidate in Cia2 locus is 
complement component C5 encoding Hc gene as the NOD allele is deficient for C5 due to the 2 
bp deletion in an exon near the 5´end. We generated sub-congenic mice having Cia2 locus in 
the B10.Q genetic background. In the present study, we investigated the source of complement 
C5 production in arthritis. It is known that liver produces most of complement proteins 
including C5 but under inflammatory conditions macrophages are also involved in C5 secretion.  
Method – In this paper, we used two different genetic strategies: congenic approach and 
heterogeneous inbred-outbred cross. Cia2 sub-congenic fragments were tested for CIA and 
CAIA susceptibility. Additionally in order to address the importance of C5 source in arthritis 
development, we performed bone marrow transfer experiments using Cia2 congenic animals. 
We transferred bone marrow from C5 deficient congenic animals into B10.Q and also 
reciprocal transfers. We have investigated the activation of two complement components 
pathways by evaluating C3b deposition.  
Results –We also have shown that congenic mice, which lack C5 are resistant to arthritis 
induced by CAIA or CIA. Cia2 locus completely suppressed arthritis development in a 
dominant fashion. Moreover, hemolytic activity is significantly diminished in C5 deficient mice 
compared to littermate controls despite sufficient classical and alternative pathway of 
complement activation. Moreover, only B10.Q mice, which received the bone marrow from 
B10.Q or from C5 deficient mice developed arthritis. The reciprocal transfer revealed 
resistance.  Further, the analysis of heterogeneous stock cross confirmed the fine mapped Cia2 
locus in arthritis development.  
Conclusions – This studies supports the common dogma that hepatocytes are the main C5 
producers even under inflammatory conditions. 
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PAPER V 
Background – Poly(N-isopropylacrylamide) (PNiPAAm) is biodegradable and biocompatible, 
thermo-responsive polymer. Previously it was shown that PNiPAAm could be used as an 
adjuvant in several immunological applications, including collagen induced arthritis in mice. 
Therefore, in paper V, we further characterized and evaluated its properties using several 
different mouse strains.  
Method – PNiPAAm was synthesized through free radical polymerization. For CIA induction 
we immunized mice with an equal mixture of collagen type II and PNiPAAm (ratio 1:1). 
Different mouse strains bearing various MHC haplotypes (H-2q,d,p or b) as well as Ncf1 mutated 
were immunized  and re-evaluated for susceptibility to arthritis using this new polymeric 
adjuvant. We also investigated the influence of Toll-like receptors using a panel of TLR-KO 
mice. Since all the TLR-KO animals are in B6 background that are not susceptible to CII- 
PNiPAAm arthritis, we investigated the anti-CII antibody response. Additionally, we 
investigated arthritis susceptibility in CII specific T cell, Vβ12 transgenic mice.  
Results – Immunization with CII and PNiPAAm induced serum cytokine production that 
indicated no major deviation toward any of the three major T helper cell populations. The new 
arthritis mouse model is toll-like receptor independent, since all immunized TLR KO mice 
developed an anti-CII response. We observed that mice with H2q haplotype were highly 
susceptible to arthritis compared to strains carrying other MHC haplotypes. Moreover, our 
results emphasized the requirement for a strong adjuvant for induction of arthritis in B6 mice. 
Additionally, we showed that CIA severity in Ncf1 mutated mice is independent of any classical 
adjuvant and arthritis induction in Vβ12 transgenic mice could be eosinophil-independent.  
Conclusions – The biocompatible and biodegradable PNiPAAm offers an unique opportunity 
to study the actual immune response to a self-protein, which is not biased towards any particular 
cytokine profile, and it’s TLR-independent.  
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CONCLUDING REMARKS 
 
So far, genetic studies have led to identify a number of QTLs that influence the development 
and pathogenesis of arthritis. However the precise identification of causative genes and 
mechanisms behind them seem to be more complicated. In the present thesis we have used two 
different genetics strategies that could help to resolve the complex task of finding genes. 
Utilization of two-generation crosses strategy very often results in large genomic fragments 
containing huge number of genes and then isolation of identified QTL into congenic lines is 
tedious and time-consuming process. However, if it is successful will definitely lead to better 
understanding of underlying mechanisms and therefore may be helpful in designing new 
therapies. Present work has focused on two loci Cia2 and Cia9 that have been found in two-
generation cross strategy. By using the several sub-congenic lines for the original Cia9 locus, 
we were able to exclude significant part of the genetic fragment and narrow down the locus to 
few genes. In this project, we investigated the role of polymorphism in FcγR cluster genes and 
its influence on arthritis development. We demonstrated that disease severity in this congenic is 
driven by polymorphism in FcγRIII and/or FcγRIIb but not FcγRIV.  
Additionally, congenic strain approach helped us to investigate the role of key factors in innate 
immunity – complement component 5 in arthritis development. We found hepatocyte-derived 
C5 is the main source even under inflammatory conditions. Moreover both the Cia2 and Cia9 
loci were also confirmed in the heterogeneous stock mice using genome- wide scan, which 
indicates the usefulness of this genetic approach to find disease-causing QTLs. The last part of 
this thesis described and characterized the new model of arthritis using synthetic thermo-
responsive polymer as an adjuvant, which allowed to study the actual immune responses to a 
self-protein. I share the belief of using animal models to gain valuable fundamental knowledge, 
which is most important to unravel the molecular pathways and mechanisms leading to 
pathology. With recent advancement in technologies, development of new therapies is very 
promising.  
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